While Avadel Pharmaceuticals plc has overperformed by 0.27%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, AVDL rose by 41.29%, with highs and lows ranging from $16.66 to $6.38, whereas the simple moving average jumped by 53.19% in the last 200 days.
On July 18, 2025, H.C. Wainwright started tracking Avadel Pharmaceuticals plc (NASDAQ: AVDL) recommending Buy. A report published by Deutsche Bank on February 11, 2025, Initiated its previous ‘Buy’ rating for AVDL. Rodman & Renshaw also rated AVDL shares as ‘Buy’, setting a target price of $27 on the company’s shares in an initiating report dated June 12, 2024. Oppenheimer Reiterated the rating as Outperform on March 05, 2024, but set its price target from $27 to $29. Needham resumed its ‘Buy’ rating for AVDL, as published in its report on March 05, 2024. H.C. Wainwright’s report from March 05, 2024 suggests a price prediction of $25 for AVDL shares, giving the stock a ‘Buy’ rating. UBS also rated the stock as ‘Buy’.
Analysis of Avadel Pharmaceuticals plc (AVDL)
Further, the quarter-over-quarter increase in sales is 64.15%, showing a positive trend in the upcoming months.
Avadel Pharmaceuticals plc’s future performance can be predicted by a variety of well-rounded types of analysis and research, with equity being one of the most crucial ones. The goal here is to ensure that your current return on equity of -3.63% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 2.38, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can be an extremely valuable indicator of volatility, and AVDL is registering an average volume of 1.37M. On a monthly basis, the volatility of the stock is set at 4.99%, whereas on a weekly basis, it is put at 4.41%, with a gain of 8.39% over the past seven days. Furthermore, long-term investors anticipate a median target price of $19.12, showing growth from the present price of $14.85, which can serve as yet another indication of whether AVDL is worth investing in or should be passed over.
How Do You Analyze Avadel Pharmaceuticals plc Shares?
Besides checking the fundamentals, you should also know how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 8.42%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 80.85% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
